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Abstract 
Numbness and pain are currently evaluated using subjective methods such as the visual analog scale (VAS). However, 
because assessment of pain can vary greatly depending on the mood and physical state of the patient at the time 
of assessment, it is best to evaluate pain objectively. pain vision PS-2100 (PV) is an analytical instrument that was 
designed to quantitatively and objectively assess sense perception and nociception in patients. The present study 
examined the correlation of subjective and objective assessment of oxaliplatin-induced peripheral neuropathy (PN) 
using VAS and PV, respectively. The mean VAS and PV scores of PN were 20.5 (range 0–100) and 27.9 (range 0–416), 
respectively. The partial correlation coefficient was 0.274 (p = 0.0003). No strong correlation was observed between 
the results and a weak correlation was observed between VAS and PV.
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Background
Oxaliplatin-induced peripheral neuropathy (PN), for 
which there is no firmly established treatment till date, is 
a critical factor that makes maintenance of chemotherapy 
difficult (Lehky et  al. 2004; Cersosimo 2005; Gamelin 
et  al. 2008). Prevention and amelioration of oxaliplatin-
induced PN are very important in improving the patient’s 
quality of life and encouraging continuation of ther-
apy. However, at present, there are no effective treat-
ments or preventive measures for oxaliplatin-associated 
neuropathy.
Pain intensity can be measured by visual analogue 
(VAS), numerical rating (NRS), or verbal rating (VRS) 
scales. VAS is one of the oldest, easiest and best validated 
measures to assess pain (Huskisson 1974). In verbal rat-
ing the patients choose one of the given verbal descrip-
tors of the intensity of pain they feel. VRS can be used 
for both intensity and unpleasantness. The McGill pain 
questionnaire (MPQ), and the short form of it (SF-MPQ) 
are the most frequently used self-rating instruments for 
pain measurement and also often used in treatment tri-
als (Melzack 1987). Both MPQ and SF-MPQ provide data 
on the various sensory and affective dimensions of pain, 
but they are not specifically designed to assess neuro-
pathic pain and their translations in languages other than 
english need further validations. Of the scales designed 
for neuropathic pain assessment, the symptom score 
scale has only been used in diabetic neuropathy (Kvines-
dal et  al. 1984), and the neuropathic pain scale does 
not include important items such as paroxysmal pain 
and numbness (Galer and Jensen 1997). Both the Leeds 
assessment of neuropathic symptoms and signs (LANSS 
scale) and neuropathic pain questionnaire have been 
developed to differentiate neuropathic from nociceptive 
pain patients, rather than tools for quantitative assess-
ment (Bennett 2001; Krause and Backonja 2003); these 
scales have only been preliminarily validated because 
they are recent and not yet widely used.
Numbness and pain are currently evaluated using sub-
jective methods such as the VAS (McCormack et al. 1988; 
DeLoach et al. 1998). VAS is used in epidemiologic and 
clinical research to measure the intensity or frequency of 
various symptoms (Paul-Dauphin et  al. 1999) including 
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peripheral neuropathy by diabetes (Daousi et  al. 2004; 
Bril et al. 2011) and chemotherapy (Liu and Wang 2012; 
Yang et  al. 2012). However, because assessment of pain 
can vary greatly depending on the mood and physical 
state of the patient at the time of assessment, it is best 
to evaluate pain objectively. Determination of pain by 
VAS is associated with a margin of error of approxi-
mately  ±  20  mm (DeLoach et  al. 1998). Therefore, a 
method for objective assessment is also required to eval-
uate drugs designed to ameliorate PN.
Recently, pain vision™ PS-2100 (PV; Nipro Co., Osaka, 
Japan) was developed and introduced in clinical prac-
tice (Matsumura et al. 2012; Lee et al. 2014; Ohtori et al. 
2014; Hiraki et  al. 2014; Kim et  al. 2014; Fukada et  al. 
2011). PV is an analytical instrument that was designed 
to quantitatively and objectively assess sense perception 
and nociception in a patient. In addition to the advan-
tage that PV can evaluate pain in a relatively short time, 
it can also evaluate pain without causing additional pain 
to patients. Although it is used in the field of anesthesiol-
ogy, there have been no reports concerning its use for the 
assessment of oxaliplatin-induced PN. Objective method 
is distinguished four different levels (Cruccu et al. 2004): 
(A) laboratory tests that use quantitative tools and meas-
ure an objective response; (B) quantitative sensory test-
ing, a measure that despite using quantitative, graded 
stimuli inevitably relies on the patient’s evaluation; (C) 
bedside examination, which relies on the physician’s 
experience and the patient’s ability and willingness to col-
laborate; and (D) pain questionnaires, tools that depend 
entirely on the patient. Therefore, PV is classified into 
(B). Because individual pain thresholds are evaluated first 
for accurate subsequent measurement with the device, 
pain intensity can be quantitatively compared among 
patients. Therefore, this device enables a more objective 
evaluation when compared with other commonly used 
methods.
In this study, we evaluated the correlation of subjective 
and objective assessment of oxaliplatin-induced PN with 
VAS and PV, respectively.
Methods
Patients
This study was approved by Fukuoka University Hos-
pital’s Institutional Review Board (No.13-4-07) and was 
performed between April 2014 and August 2014.
Patients with histologically proven metastatic and unre-
sectable colorectal adenocarcinomas who had not under-
gone chemotherapy or who had completed adjuvant 
chemotherapy during the last 6  months were enrolled 
in the study. Patients were excluded if they had a mental 
disorder or poor mental health that made it impossible 
to understand the concepts of VAS and PV. Patients were 
also excluded if they had any peripheral sensory neuropa-
thy or musculoskeletal pain before chemotherapy that 
may disrupt the measurement of quantitative pain. All 
patients provided written informed consent.
Chemotherapy
A total of 58 patients with advanced or recurrent colo-
rectal cancer (CRC) who received XELOX+bevacizumab 
therapy (7.5 mg/kg bevacizumab and 130 mg/m2 oxalipl-
atin on day 1 and 2000 mg/m2 capecitabine on days 1–14, 
every 3 weeks) or XELOX therapy (130 mg/m2 oxaliplatin 
on day  1 plus 2000  mg/m2 capecitabine on days 1–14, 
every 3  weeks) (Yoshida et  al. 2015a, b) at the Depart-
ment of Gastroenterological Surgery, Fukuoka Univer-
sity Hospital between April 2014 and August 2014 were 
included.
Visual analog scale (VAS)
VAS is a simple and commonly used method for evaluat-
ing variations in pain intensity. Subjects are instructed to 
indicate the intensity of pain at rest and during mobiliza-
tion by marking on a 100-mm horizontal line anchored 
with ‘‘0 (no pain)’’ on the left edge and ‘‘100 (worst imagi-
nable pain)’’ on the right edge.
Pain vision
The PV system was developed as a medical device to 
evaluate pain intensity as a numerical value. The prin-
ciple of measurement of this system is to compare a 
unique electrical stimulation with the pain that the 
patient is experiencing. An electrical stimulation with-
out pain, whose intensity is equivalent to that of the 
pain experienced by the patient, is applied, and the cur-
rent value of this electrical stimulation is defined as the 
“pain-equivalent current.” The sensitivity (threshold) of 
the patient for the electrical stimulation is defined as 
the “minimum perceived current,” which is intended to 
eliminate variations between individuals. Using these 
two values, pain intensity is defined by the following 
formula:
Pain intensity  =  (pain-equivalent current−minimum 
perceived current)/minimum perceived current × 100.
An electrode is attached to the medial side of the 
upper arm. An electrical current is applied (50  Hz; 
0–150  uA rms; pulse width: 0.3  ms), and the stimula-
tion is increased. The patient is instructed to press a but-
ton when she/he perceives this stimulation for the first 
time; the current at this point is defined as the “mini-
mum perceived current” value. As the stimulation cur-
rent is increased, the patient is instructed to press the 
switch when she/he feels that the intensity of the stim-
ulation current is equivalent to that of the pain she/
he is experiencing. The current at this point is defined 
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as the “pain-equivalent current” value. Using the values 
obtained, “pain intensity” is calculated using the afore-
mentioned formula. When there is no pain, the value is 
0, and it increases according to the degree of pain, with 
no upper limit. Each measurement is simple and can be 
completed within a few minutes.
Statistical analyses
Data were collected and analyzed using SAS Version 9.3 
(SAS Institute, Cary, North Carolina, USA). To inves-
tigate the reliability of the device in terms of internal 
consistency, we assessed the QPD score twice. Data are 
reported as mean  ±  standard deviation (SD), median 
(interquartile range 25–75  %), or number of partici-
pants (percentages). Partial correlation analysis was 
performed to estimate the relationship between PV and 
VAS after adjusting for sex and subject. Namely, the 
correlation coefficient between PV and VAS was com-
puted using residual values of the mixed-effects model 
including sex as a fixed effect and subject as a random 
effect. P values of 0.05 or less were considered statisti-
cally significant.
Results
Between April and August 2014, a total of 64 patients 
received chemotherapy for metastatic CRC. Six patients 
were excluded according to the selection criteria (five 
patients with ECOG PS 2 were excluded, and one patient 
was excluded because of inadequate hematological, renal, 
and liver functions.). A half of patients had any neuro-
pathic pain therapy (duloxetine two patients, pregaba-
lin eight patients, tramadol 12 patients and oxycodone 
seven patients). The final cohort included 40 men and 18 
women ranging in age from 43 to 80 years (median age, 
65  years). The patient characteristics are presented in 
Table 1.
Among the included patients, 81.0 % had ECOG PS 0 
at baseline, with the liver being the most common site of 
metastasis. The median cumulative amount of oxaliplatin 
was 1751 mg/body (345–5903), and the number of cycles 
was 10.
Grade 3 or higher hemotoxicity and grade 3 or higher 
non-hematological toxicity were noted in 12.5 and 17.4 % 
of patients, respectively.
PN was assessed using both VAS and PV a total of 173 
times. The mean VAS and PV scores of PN were 20.5 
(range 0–100) and 27.9 (range 0–416), respectively. The 
partial correlation coefficient after adjusting for sex and 
subject was 0.274 (p = 0.0003) (Fig. 1).
Discussion
VAS is one of the most common methods used for the 
evaluation of pain (McCormack et al. 1988). The NRS and 
the 4-point VRS are difficult to use when evaluating PN 
because they cannot distinguish small changes in pain; 
in contrast, VAS can distinguish changes in pain with 
the highest sensitivity (Seymour 1982). VAS is a subjec-
tive method of grading pain that the patient is experienc-
ing currently in comparison with the most intense pain 
that the patient has ever experienced (Babul et al. 1993). 
Because of the ease of its use, VAS became a popular 
tool for quantifying pain relief and pain intensity. It has 
been found to be a valid and reliable means of assessing 
pain, depression, anxiety, and mood (McCormack et  al. 
1988). VAS tends to focus only on pain intensity, with 
an increased risk of over-simplification of the experi-
ence (Bonica et  al. 1990). Furthermore, actual measure-
ments are relative only to the individual being assessed. 
Identical stimuli applied to different individuals can yield 
markedly different scores.
A newly developed device, PV, has recently been used 
for the quantitative analysis of pain perception and sensa-
tion, measuring pain intensity as the “degree of pain.” In 
clinical practice, this method has been used for evaluating 
not only chronic pain, such as fibromyalgia (Osada et al. 
2011) or lower back pain due to spondylolisthesis (Lee 
et al. 2014), but also for acute pain caused by the removal 
of adhesive wound dressing materials (Matsumura et  al. 
2012). Previous studies have shown that PV is a useful 
device that can evaluate pain objectively in various fields 
and for the quantitative assessment of sensory nerve dys-
function (Baden et  al. 2011; Okamoto et  al. 2013; Seno 
et al. 2011). This system is based on the provision of alter-
native painless sensory stimulation equivalent to pain 
(through the stimulation of sensory nerve fibers Aβ and 
Aδ) and the measurement of the intensity of the stimula-
tion. However, there is no report of use of PV to evaluate 
PN. Prevention and improvement of oxaliplatin-induced 
PN is very important to improve the patient’s quality of 
life and to encourage continuation of treatment. However, 
at present, there are no effective treatments or preventive 
measures for oxaliplatin-associated neuropathy.
To the best of our knowledge, no previous study has 
investigated oxaliplatin-induced PN quantitatively using 
Table 1 Baseline characteristics of  patients who received 
chemotherapy
XELOX+BV/XELOX 40/18
Median age (range) 65 (43–80)
Male/female 68.9/31.1 %
ECOG PS 0/1 81.0/19.0 %
Primary tumor colon/rectum 53.4/46.6 %
Oxaliplatin 1751 mg/body (345–5903)
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electrical stimulation. The limitation of this study include 
only VAS as a subjective evaluation that did not allow 
adequate assessment of PN. Accordingly, neuropathic 
pain questionnaire, leeds assessment of neuropathic 
symptoms and signs scale and Douleur Neuropathique 
en four Questions needs to be performed using well-
matched groups of patients to confirm our findings. We 
believe that the effect of the drug for oxaliplatin-induced 
PN should be evaluated objectively.
Conclusions
Although both assessments evaluated the same events, 
no strong correlation was observed between the results 
and a weak correlation was observed between VAS and 
PV. These results suggest that because VAS and PV each 
measure different factors, both are needed to evaluate 
oxaliplatin-induced PN with the aim of aiding treatment. 
These findings are expected to help in the amelioration 
of PN through the use of objective assessment and to 
support future clinical trials associated with oxaliplatin-
induced PN.
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